Dysport vs Daxxify: Diffusion and Duration as the Two Axes That Matter

Two different pitches

Dysport (abobotulinumtoxinA) is an established product, often noted for its spread/diffusion characteristics that some injectors favor for broad areas, dosed in its own units with a conversion from Botox. Daxxify (daxibotulinumtoxinA) is positioned primarily around duration — the pitch is a potentially longer interval between treatments. So the comparison is really between a familiar, established profile and a duration-forward proposition, which means the "better" choice depends on what a given patient values.

Duration changes the math

For Daxxify especially, the relevant economics aren't cost-per-unit but cost-per-month-of-effect and cost-per-visit. If a patient genuinely stretches their interval, a higher per-treatment cost can still make sense on annual spend and visit frequency; if they don't benefit from the longer interval, it may not. That's a patient-specific calculation, not a blanket win for duration — and it's the right lens for evaluating Daxxify's positioning rather than taking "lasts longer" at face value.

The owner's decision

Carrying a duration option alongside an established workhorse can serve patients who value fewer visits — but it carries the familiar cost of a second product: operational complexity and rebate/loyalty fragmentation that can weaken your standing on your primary toxin. So the question is whether the duration demand in your patient base justifies the second product. As always, the per-patient clinical choice belongs to your injectors; the inventory and positioning decision is yours.

What to do

• Understand the two pitches — Dysport's established, familiar profile versus Daxxify's duration positioning — and match each to patient priorities.
• Evaluate Daxxify on cost-per-month-of-effect, not duration alone, since the value is patient-specific.
• Weigh the second-product cost (operational and rebate fragmentation) against genuine duration demand before carrying both.
• Leave the per-patient clinical choice to injectors, and own the inventory and positioning decision.